Analyzing XBiotech (XBIT) and Its Rivals
XBiotech (NASDAQ: XBIT) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare XBiotech to similar companies based on the strength of its valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.
This is a breakdown of current ratings and recommmendations for XBiotech and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
XBiotech presently has a consensus price target of $13.00, suggesting a potential upside of 211.75%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.74%. Given XBiotech’s higher probable upside, analysts plainly believe XBiotech is more favorable than its rivals.
Risk & Volatility
XBiotech has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, XBiotech’s rivals have a beta of 6.02, suggesting that their average share price is 502% more volatile than the S&P 500.
Insider & Institutional Ownership
11.0% of XBiotech shares are owned by institutional investors. Comparatively, 50.0% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 35.7% of XBiotech shares are owned by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This table compares XBiotech and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares XBiotech and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|XBiotech Competitors||$284.49 million||$33.78 million||81.69|
XBiotech’s rivals have higher revenue and earnings than XBiotech. XBiotech is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
XBiotech rivals beat XBiotech on 8 of the 12 factors compared.
XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system. Xilonix is a therapeutic antibody, which specifically neutralizes interleukin-1 alpha (IL-1a). Its pipeline includes various human antibodies for treating diseases, such as cancer, vascular disease, inflammatory skin disease and diabetes. The Company has completed a Phase III study in Europe for the treatment of symptomatic colorectal cancer. It also investigated its lead product candidate in clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS).
Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.